1 f novel compounds was determined by in vitro
radioreceptor affinity assays selective for serotonin 5-
2 during sample processing conditions and that
radioreceptor assay is highly selective for the detectio
3 ags, binds a CRF antagonist, astressin, in a
radioreceptor assay using [(125)I-d-Tyr(0)]astressin.
4 C-gamma, by myo-inositol 1,4,5-trisphosphate
radioreceptor assay, demonstrated that depletion of gluc
5 When examined for the TNF receptors by the
radioreceptor assay, flow cytometry, or Western blot ana
6 cholinergic activity (SAA), as measured by a
radioreceptor assay, quantifies a person's overall antic
7 inergic activity, measured at study entry by
radioreceptor assay, was available for 49 patients.
8 Using a
radioreceptor assay, we show that suramin interfered wit
9 um 25(OH)D concentrations were measured by a
radioreceptor assay.
10 nt was measured by Western blotting and by a
radioreceptor assay.
11 hosphate (IP3) production in an IP3-specific
radioreceptor assay.
12 ,4,5-trisphosphate (IP3) was measured with a
radioreceptor assay.
13 oric acid and then measure the NAADP using a
radioreceptor assay.
14 the FITC-hapten immunoassay and a reference
radioreceptor assay.
15 ype and mutant hFSH activities determined in
radioreceptor assays (ID50) and in vitro bioassays (ED50
16 and receptor protein levels were measured by
radioreceptor assays and Western blotting.
17 In support of this hypothesis,
radioreceptor assays with transfected CHO cell lines sta
18 In
radioreceptor assays, 125I-labeled CTX binds to a protei
19 Radioreceptor binding analysis indicated that in the adu
20 Subsequent
radioreceptor binding analysis indicated that the drug-i
21 Currently available
radioreceptor binding and enzymatic assays require exten
22 on of IP3 was quantified using a competitive
radioreceptor binding assay.
23 Radioreceptor binding assays and covalent cross-linking
24 i.e., NK-1 receptors) has been inferred from
radioreceptor binding assays and functional assays and,
25 monstrated by luciferase reporter and Ang II
radioreceptor binding assays.
26 Radioreceptor binding studies in rat brain preparations
27 125I-labeled TGF-beta1 was used in a
radioreceptor-
binding assay as an index of functional re
28 ural analogs, were obtained from D1 dopamine
radioreceptor-
binding assays.
29 range of CNS receptor-active ligands and CNS
radioreceptor screening assays indicate that the pharmac
30 , a compound commonly used today for peptide
radioreceptor therapy.